scholarly journals Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort

2016 ◽  
Vol 132 (4) ◽  
pp. 625-634 ◽  
Author(s):  
Emeline Tabouret ◽  
◽  
Anh Tuan Nguyen ◽  
Caroline Dehais ◽  
Catherine Carpentier ◽  
...  
Keyword(s):  
Who Classification ◽  
Prognostic Impact ◽  
Diffuse Gliomas

scholarly journals Increased proliferation is associated with CNS invasion in meningiomas

2021 ◽  
Author(s):  
Felix Behling ◽  
Christina Fodi ◽  
Sophie Wang ◽  
Johann-Martin Hempel ◽  
Elgin Hoffmann ◽  
...  
Keyword(s):  
Immunohistochemical Staining ◽  
Proliferative Activity ◽  
Who Classification ◽  
Prognostic Markers ◽  
Proliferative Potential ◽  
Prognostic Impact ◽  
Proliferation Marker ◽  
Automatic Quantification ◽  
Histopathological Evidence

Abstract Introduction Meningiomas are the most common benign intracranial neoplasms. CNS invasion in meningiomas has been integrated into the 2016 WHO classification of CNS tumors as a stand-alone criterion for atypia. Since then, its prognostic impact has been debated based on contradictory results from retrospective analyses. The aim of the study was to elucidate whether histopathological evidence of CNS invasion is associated with increased proliferative potential. Methods We have conducted a quantified measurement of the proliferation marker Ki67 and analyzed its association with CNS invasion determined by histology together with other established prognostic markers of progression. Routine, immunohistochemical staining for Ki67 were digitalized and automatic quantification was done using Image J software. Results Overall, 1718 meningiomas were assessed. Histopathological CNS invasion was seen in 108 cases (6.7%). Uni- and multivariate analysis revealed a significantly higher Ki67 proliferation rate in meningiomas with CNS invasion (p < 0.0001 and p = 0.0098, respectively). Conclusions Meningiomas with histopathological CNS invasion show a higher proliferative activity.

The 2016 revision of the WHO Classification of Central Nervous System Tumours: retrospective application to a cohort of diffuse gliomas

2017 ◽  
Vol 137 (1) ◽  
pp. 181-189 ◽  
Author(s):  
Te Whiti Rogers ◽  
Gurvinder Toor ◽  
Katharine Drummond ◽  
Craig Love ◽  
Kathryn Field ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Who Classification ◽  
Central Nervous System Tumours ◽  
Diffuse Gliomas

scholarly journals Cost-effectiveness of IDH testing in diffuse gliomas according to the 2016 WHO classification of tumors of the central nervous system recommendations

2017 ◽  
Vol 19 (12) ◽  
pp. 1640-1650 ◽  
Author(s):  
John C DeWitt ◽  
Justin T Jordan ◽  
Matthew P Frosch ◽  
Wesley R Samore ◽  
A John Iafrate ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Cost Effectiveness ◽  
Who Classification ◽  
Diffuse Gliomas ◽  
The Central Nervous System ◽  
Classification Of Tumors

Practical Implications of the Updated WHO Classification of Brain Tumors

2018 ◽  
Vol 38 (01) ◽  
pp. 011-018 ◽  
Author(s):  
Felix Sahm ◽  
Maria Martinez-Lage
Keyword(s):  
Who Classification ◽  
Integrated Approach ◽  
Central Nervous System Tumors ◽  
Genetic Characteristics ◽  
Recent Developments ◽  
Diffuse Gliomas ◽  
Definition Of ◽  
Novel Concept ◽  
Practical Implications

AbstractThe updated 2016 WHO classification of Central Nervous System tumors introduced a novel concept of neuropathology diagnostics. Molecular parameters are now included into the definition of several entities. This evolution from a previously purely histology-based classification to an integrated approach of histology and genetic characteristics has implications in daily diagnostic and clinical practice. Both the spectrum of diagnostic workup demanded from the neuropathologist and the range of relevant markers to be considered by clinicians and clinical investigators have increased. This article reviews the major changes in the classification of diffuse gliomas, ependymoma, and medulloblastoma, the practical consequences for diagnostics and clinical trials, and points toward recent developments that potentially will influence the next update of the classification.

scholarly journals Brain Invasion in Meningioma—A Prognostic Potential Worth Exploring

Cancers ◽  
2021 ◽  
Vol 13 (13) ◽  
pp. 3259
Author(s):  
Felix Behling ◽  
Johann-Martin Hempel ◽  
Jens Schittenhelm
Keyword(s):  
Who Classification ◽  
Prognostic Impact ◽  
Brain Invasion ◽  
Risk Of Recurrence ◽  
Imaging Characteristics ◽  
Alternatives Assessment ◽  
Potential Prognostic Factor ◽  
Treatment Alternatives

Most meningiomas are slow growing tumors arising from the arachnoid cap cells and can be cured by surgical resection or radiation therapy in selected cases. However, recurrent and aggressive cases are also quite common and challenging to treat due to no established treatment alternatives. Assessment of the risk of recurrence is therefore of utmost importance and several prognostic clinical and molecular markers have been established. Additionally, the identification of invasive growth of meningioma cells into CNS tissue was demonstrated to lead to a higher risk of recurrence and was therefore integrated into the WHO classification of CNS tumors. However, the evidence for its prognostic impact has been questioned in subsequent studies and its exclusion from the next WHO classification proposed. We were recently able to show the prognostic impact of CNS invasion in a large comprehensive retrospective meningioma cohort including other established prognostic factors. In this review we discuss the growing experiences that have been gained on this matter, with a focus on the currently nonuniform histopathological assessment, imaging characteristics and intraoperative sampling as well as the overall outlook on the future role of this potential prognostic factor.

Incidence and Biologic Features of 5q Deletion and 5q- Syndrome in Myelodysplastic Syndrome in Korea; According to Reclassification of Myelodysplastic Syndrome by WHO 2008.

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 2778-2778
Author(s):  
Hye Ryun Lee ◽  
Dae Sik Hong ◽  
Dae Young Zang ◽  
Hong Ghi Lee ◽  
Hwi-Joong Yoon ◽  
...  
Keyword(s):  
Myelodysplastic Syndrome ◽  
Who Classification ◽  
Chromosomal Abnormalities ◽  
Refractory Anemia ◽  
Fish Analysis ◽  
Prognostic Impact ◽  
Chromosome 5 ◽  
Prognostic Features ◽  
5Q Deletion

Abstract Abstract 2778 Poster Board II-754 Introduction: Interstitial deletions involving the long arm of chromosome 5, one of the good prognostic factors, are the most common chromosomal abnormality either as a sole or in combination with other abnormalities in myelodysplastic syndromes (MDS). However, the prognostic impact of del(5q) accompanied by additional chromosome abnormalities remains controversial. We investigated the hematologic, cytogenetic and prognostic features of del(5q) in MDS. Also, we mapped the deleted region on 5q by fluorescence in situ hybridization (FISH), whether the difference of deleted region between 5q- syndrome and MDS with del(5q) accompanied by additional abnormalities makes the clinical and prognostic differences. Methods: 137 adult patients, newly diagnosed as de novo MDS in Seoul National University Hospital from April 2000 through March 2009, were enrolled. We reclassified MDS subtypes according to WHO classification 2008. To compare the hematologic, cytogenetic and prognostic features according to presence of del(5q), we categorized the patients with del(5q) into 3 groups: patients with additional chromosomal abnormalities with del(5q) as 'MDS with del(5q)'; patients with other chromosomal abnormalities other than del(5q) as 'MDS with other chromosomal abnormalities (CA)'; and patients with isolated del(5q) as '5q- syndrome'. Also, the mapping with FISH for EGR1, CSF1R, and PDGFRβ on 5q, was performed in conjunction with G-banding to all patients and additional 16 patients with alleged del(5q) by G-banding from Korean MDS working party. Results: According to the new WHO classification of 2008, the 33 refractory anemia patients according to the previous WHO classification of 2001 were reclassified into refractory cytopenias with unilineage dysplasia (13 patients), refractory cytopenia with multilineage dysplasia (six patients) and MDS - unclassified (14 patients) (Fig 1). The median age of Korean MDS was 59 years, and the frequencies of 5q- syndrome and 5q deletion was 2.2% (3/137 patients) and 15.3%, respectively. Among 137 patients, 17 patients were grouped into 'MDS with del(5q)', and 53 patients into 'MDS with other CA'. The 'MDS with del(5q)' were significantly older and showed higher % of blasts in PB and BM than 'MDS with other CA'. And, they were categorized into higher risk group according to the International Prognostic Scoring System (IPSS) (Table 1). As a results of mapping for EGR1, PDGFRβ and CSF1R, deletion of all 3 regions was 93.3% in patients of 'MDS with del(5q)' and 66.7% in patients of '5q- syndrome', showing no difference in deleted genes between the two groups. Half (53%) of patients of 'MDS with del(5q)' accompanied complex abnormalities including chromosome 7 abnormalities. The del(5q) was detected only by FISH, showing discrepant results between G-banding and FISH analysis. Especially, marker chromosomes by G-banding in some patients were proved to be chromosome 5 with del(5q) by FISH. Conclusion: The biologic and prognostic features of MDS in Korea seem to be markedly different from those of Caucasian; younger age and low frequency of 5q- syndrome. The incidence of complex cytogenetic abnormalities including del(5q) was higher than that of Caucasian, while that of isolated del(5q) was quite low in Korea, which can explain that higher proportion of MDS with del(5q) belongs to higher risk IPSS group. And, we suggest FISH for del(5q) at initial diagnosis and during follow-up after treatment of MDS with alleged del(5q), since the presence of del(5q) in MDS is important for choosing the lenalidomide treatment. Disclosures: No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document